Andrew Satz, Co-Founder and CEO of EVQLV, talks with EisnerAmper's TechTalk host Fritz Spencer about his startup’s mission to leverage advances in computation to revolutionize the discovery and engineering of therapeutic antibodies. In this episode, Andrew discusses how his proprietary platform generates “intellectual property as a service” for fully human antibodies, significantly reducing development costs and time. Tune in to hear how EVQLV aims to accelerate the creation of personalized medicines, paving the way for a future where treatments are tailored to each individual patient.